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Background: Suspected nonischemic cardiomyopathy (NICM) is a common clinical setting with highly variable
prognosis. Early noninvasive risk-stratification is important for justification of invasive examinations, specific treatment
and patient surveillance. We studied the additional prognostic value of late gadolinium enhancement (LGE) and
segmental wall motion abnormality (SWMA) extent on cardiovascular magnetic resonance (CMR) compared to traditional
risk factors in suspected NICM.
Methods: In this observational cohort study, we enrolled 86 consecutive patients referred for CMR due to suspected
NICM. Patients with ischemic cardiomyopathy were excluded. CMR images were analysed for left ventricular LGE and
SWMA extents and patients were followed-up for major adverse cardiac events (MACE), including cardiovascular death,
aborted sudden death and cardiac transplantation.
Results: Of 86 patients (median age: 53 years, 45% female), mainly presenting with ventricular arrhythmias (40%) and
congestive heart failure (44%), 76% were finally diagnosed with NICM, 17% with left ventricle hypertrophy and 7% with
idiopathic arrhythmia. On CMR, 61 patients (71%) had LGE and 56 (65%) SWMA. During median follow-up of 835 days,
15 patients (17%) reached MACE. In univariant analysis, LGE volume (hazard ratio [HR] 1.028 per 1% increase in LGE,
p < 0.001), left ventricular ejection fraction (LVEF) (HR 0.959, p = 0.009) and SWMA score (HR 1.067, p = 0.012) had
strongest associations with MACE. In multivariate analysis, the best overall model for event prediction included LGE
volume (HR 1.027, p = 0.003), sustained ventricular tachycardia (HR 4.7, p = 0.011) and LVEF (HR 0.962, p = 0.034).
Among patients with LGE, there was an event rate of 26% (14 of 61) versus 4% (1 of 25) in patients without LGE
(p = 0.041, Log-rank). The highest event rate was observed in patients with LGE volume of ≥17%. Patients without
SWMA did not experience MACE (p = 0.002, Log-rank), giving additional information in the subgroup of patients with
preserved LVEF (≥50%).
Conclusions: In suspected NICM, presenting with ventricular arrhythmias or heart failure, LGE extent gives additional
prognostic information compared to traditional risk factors, while the absence of SWMA may give prognostic
information beyond normal LVEF. Even though the final diagnosis is uncertain in NICM, extensive amount of LGE
should be considered as a sign of poor prognosis.
Keywords: Cardiomyopathy, Nonischemic cardiomyopathy, Cardiovascular magnetic resonance imaging, Late
gadolinium enhancement, Segmental wall motion abnormality, Prognosis, Risk-stratification* Correspondence: pauli.poyhonen@helsinki.fi
1Heart and Lung Center, Division of Cardiology, Helsinki University Central
Hospital, Po BOX 340, 00029 HUCH Helsinki, Finland
Full list of author information is available at the end of the article
© 2014 Pöyhönen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Pöyhönen et al. BMC Cardiovascular Disorders 2014, 14:110 Page 2 of 10
http://www.biomedcentral.com/1471-2261/14/110Background
Nonischemic cardiomyopathy (NICM) is a common
diagnostic challenge in clinical cardiology. NICMs are
a diverse group of myocardial diseases associated with
mechanical or electrical dysfunction and usually in-
appropriate ventricular hypertrophy or dilatation, not
related to atherosclerosis [1]. The etiology of NICM may
be genetic, acquired or secondary to systemic disease,
with highly variable clinical presentation and prognosis
[2,3]. However, the specific diagnosis of NICM is initially
often unexplained and reaching the final diagnosis may
be a timely process. Thus, early risk-stratification of
NICM is valuable for justification of potentially harmful
invasive examinations [4] and proper patient surveillance.
Although left ventricular ejection fraction (LVEF), ven-
tricular tachycardia (VT) and NYHA functional classifi-
cation are all well known predictors of cardiac mortality
[5], there is increasing evidence that noninvasive cardio-
vascular magnetic resonance (CMR) imaging with late
gadolinium enhancement (LGE) provides additional in-
formation in the risk-stratification of NICM [6-9].
The prognostic value of LGE has been shown in
several specific cardiac diseases, including ischemic and
nonischemic cardiomyopathies [10-15]. LGE, i.e. delayed
enhancement on CMR images after intravenous injec-
tion of gadolinium-contrast, visualizes increases in the
regional extracellular space related to myocardial necro-
sis, fibrosis, oedema or infiltration. Ideally, the prognos-
tic value of LGE should be interpreted in the context of
the specific disease, since the etiology of NICM itself
carries a prognostic value [3]. However, since the specific
diagnosis of NICM often remains unclear even after
CMR, the prognostic value of LGE must frequently be
considered in suspected or newly diagnosed NICM.
There is limited information on the prognostic value of
LGE in nonselected consecutive patients with newly di-
agnosed NICM, which reflects the usual real-life clinical
scenario [8]. Furthermore, most studies have evaluated
the prognostic value of the presence of LGE [9], and there
are only few studies on quantifying the extent of LGE in
NICM, considering the best prognostic ability [10,16,17].
In this study, the visual scoring method based on the
standard 17-segment model was used to estimate the
global extent of LGE in the left ventricle (LV) [18]. This
method has been shown to be rapid and accurate method
to estimate LGE both in ischemic and nonischemic cardio-
myopathies [7,19,20].
Segmental wall motion abnormalities (SWMA), visual-
ized by echocardiography, have been used for long to
detect myocardial ischemia and viability in ischemic
cardiomyopathy [21]. However, CMR with standard cine-
imaging has been shown to be the most accurate and
reproducible method to study left ventricular regional
function [22,23]. Recently, visual scoring of SWMA hasbeen shown to be accurate and reproducible method to
estimate LVEF, known strong predictor of cardiac mortal-
ity [24]. Nevertheless, it is unclear if SWMA gives add-
itional prognostic information beyond LVEF in NICM.
In this cohort study, we evaluated the additional prog-
nostic value of LGE and SWMA extent on CMR com-
pared to traditional cardiac risk factors in a common
clinical setting of suspected NICM. We hypothesized
that even though the eventual diagnosis is uncertain in
suspected NICM, LGE or SWMA extent might provide
valuable information in early risk-stratification.
Methods
Study design and patient selection
This observational cohort study was performed in the
Heart and Lung Center at the Helsinki University
Central Hospital (HUCH). Altogether 98 consecutive
patients referred for LGE CMR due to suspected NICM
between November 2008 and April 2010 (18 months)
were enrolled to the study. All enrolled patients had sus-
pected NICM, i.e. symptoms of heart failure, mechanical
and/or electrical cardiac dysfunction, usually associated
with inappropriate ventricular dilatation or hypertrophy,
or cardiac enzyme elevation, not related to atherosclerosis
[1]. Before CMR, no patient had history of myocardial in-
farction or documented significant coronary artery disease
(CAD) defined as > 50% stenosis in two or more epicardial
vessels or > 50% stenosis in left main or proximal left an-
terior descending artery [25]. Also, no patient had known
valvular or congenital heart disease. After CMR, six pa-
tients were lost due to lack of complete baseline data and
another six patients were excluded due to ischemic cardio-
myopathy. Thus, eventually 86 patients were eligible for
analysis. The study protocol was approved by the institu-
tional review board of HUCH. All data in this study were
analysed retrospectively.
Data acquisition
Medical records were reviewed for traditional cardiovas-
cular prognostic factors: patient demographics, cardio-
vascular risk factors, cardiac symptoms and clinical
signs. Patients underwent extensive cardiac evaluation
for underlying diagnosis: CMR (n = 86, 100% of patients),
echocardiography (n = 86, 100%), coronary angiography
(n = 47, 55%), stress and rest single-photon emission
computed tomography (SPECT) (n = 4, 5%), one or
more endomyocardial biopsies (n = 41, 48%; total num-
ber of biopsy procedures 55), positron emission tomog-
raphy (PET) (n = 21, 24%), electrophysiological study
(n = 14, 16%), mediastinoscopy (n = 4, 5%) and explant
histopathology after heart transplantation (n = 2, 2%).
The final diagnosis was reached using all available clinical
information following the AHA 2006 guidelines of classi-
fication of cardiomyopathies [1].
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CMR, based on the decision of treating cardiologist.
Patients examined with neither angiography nor SPECT
(n = 37, 43%) were relatively young (median age = 45 years),
had only few CAD risk factors (the median number of risk
factors was 1 out of 5 [dyslipidemia, hypertension, diabetes,
smoking, family], interquartile range 0–1) and evident non-
ischemic etiology for symptoms. Patients were excluded
due to ischemic cardiomyopathy if they had documented
significant CAD, definition see above, presence of revers-
ible perfusion defect in stress and rest SPECT or presence
of CAD in explanted hearts.
Nonsustained VT was defined as six or more consecu-
tive ventricular complexes lasting less than 30 seconds,
and sustained VT with a duration of 30 seconds or more.
Congestive heart failure (CHF) was defined using the 2008
guidelines of the European Society of Cardiology with the
requirement of objective sign of fluid retention.
CMR protocol and image analysis
CMR imaging was performed with a 1.5-T imager
(Avanto; Siemens, Erlangen, Germany) using 12-channel
body-array coil as a receiver. Breath-hold cine CMR was
performed using retrospectively electrocardiographically
gated segmented true fast imaging with steady-state
free-precession (SSFP). Cine CMR images were acquired
in vertical, horizontal long-axis and short-axis planes
covering the whole left ventricle. Typical imaging pa-
rameters were TR/TE 3.0/1.6 ms, flip angle 52 degrees,
256 x 256 matrix and 240 x 340 mm field of view. Slice
thickness was 6 mm and interslice gap 100% (6 mm).
The temporal resolution was 42 – 49 ms. Five to fifteen
minutes after intravenous injection of a contrast agent
(gadoterate meglumine, Dotarem® 0.1 mmol/kg) LGE
images were acquired in the same views as for cine im-
ages, using inversion-recovery turbo fast-low angle shot
(FLASH). Typical imaging parameters were TR/TE 2.58/
2.3 ms, flip angle 50 degrees, 256 x 256 matrix, and
240 × 340 mm field of view. Slice thickness was 8 mm and
interslice gap 100% (8 mm). Inversion times were opti-
mized to null the signal intensity of normal myocardium
(240 – 360 ms).
CMR images were analysed for the presence and ex-
tent of left ventricular LGE and SWMA by experienced
cardiac radiologist blinded to clinical outcome. LGE was
evaluated using the previously described visual scoring
method based on the standard 17-segment model of the
left ventricle [18]. In each segment, the percentage of
enhancement was visually estimated and scored as 0
(no enhancement), 1 (0 – 25% enhancement), 2 (26 – 50%
enhancement), 3 (51 – 75% enhancement) or 4 (76 – 100%
enhancement). The global extent of LGE (LGE score) was
calculated summing all segmental scores. To estimate the
volume of LGE in the left ventricle, LGE score was thenexpressed as a percentage of the total maximum score
(4 × 17 = 68) using formula: 100 × (LGE score) / 68.
Similarly, SWMA was visually estimated based on the
17-segment model using the scoring method validated
for echocardiography and later used in CMR studies
[21]. The degree of wall motion abnormality in each seg-
ment was scored as 0 (normokinesia), 1 (hypokinesia), 2
(akinesia) or 3 (dyskinesia). The global SWMA score of
the left ventricle was then calculated as the sum of all
segmental scores.
Patient follow-up and endpoints of the study
After CMR, patients were followed-up for major adverse
cardiac events (MACE), including cardiovascular death,
aborted sudden death or cardiac transplantation until
April 30th 2012, based on information from medical re-
cords and mortality data from the national registry of
Statistics Finland. For MACEs, event times were measured
from the time of CMR to the first event. Aborted sudden
death was defined as documented resuscitation from
cardiac arrest or appropriate implantable cardioverter-
defibrillator therapy, i.e. antitachycardia pacing or shock,
for VT or ventricular fibrillation (VF). To meet the end-
point criteria, an event had to be distinct from baseline
arrhythmias.
Statistical analysis
Continuous variables are presented as median (interquartile
range [IQR]) and categorical variables as frequency (%),
unless otherwise mentioned. Comparison between con-
tinuous variables was performed with Mann–Whitney
U test and between categorical variables with Pearson
Chi-Square test with continuity correction, Fisher’s exact
test or Mann–Whitney U test. A p-value of < 0.05 was
considered statistically significant and all statistical
tests were 2-sided. Univariate Cox regression analysis
was performed to study the prognostic significance of
each predictive factor separately. Variables with statistical
significance p < 0.05 (entry cut-off ) were considered in
the multivariate model. Forward stepwise multivariate
Cox regression analysis was performed to study the inde-
pendency of predictive variables, with a removal cut-off
value of p = 0.05 for the final model. The number of vari-
ables in the model was limited to three in accordance
with the limited number of events during follow-up
(at least 5 events per each covariate). All variables in the
multivariate model were tested to satisfy Cox proportional
hazard assumption by plotting hazard function and loga-
rithm of hazard function. If needed, continuous variables
were made to dichotomous and cut-off values were taken
from literature or close to median. Kaplan-Meier method
was used to plot and compare (Log rank) survival curves.
Receiver operating characteristic (ROC) curves were used
to find the best cut-off values of LGE extent and SWMA
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for the prediction of events. Statistical analysis was per-
formed on SPSS 20 statistical package (SPSS, Chigaco, IL).
Results
Patient characteristics
Of the 86 patients with suspected NICM the median age
was 53 (42 – 61) years at the time of CMR and 39 (45%)
were female. Most common symptoms at presentation
were decline in functional capacity (67%), ventricular ar-
rhythmias (40%) and CHF (44%). After extensive cardiac
examinations, of all cohort patients suspected for NICM
at baseline, 65 patients (76%) were finally diagnosed with
NICM, 15 (17%) with left ventricle hypertrophy and 6
(7%) with idiopathic arrhythmia, see Table 1. The most
frequent disease entities were inflammatory cardiomyop-
athy (n = 23, 27%) and dilated cardiomyopathy (DCM)
(n = 22, 26%). If a patient had several concomitant car-
diac diseases, the disease considered to cause the current
cardiac symptoms is presented.
Of all 86 patients, altogether 61 (71%) had left ven-
tricular LGE present on CMR. The median LGE extent
in all patients was 7% (0 – 25%) of LV volume and in
LGE positive patients alone 13% (6 – 32%). Altogether
56 patients (65%) had SWMA, with a median SWMA
score 4 (0 – 12) in all patients and 7 (4 – 19) in SWMA
positive patients. In all 1462 segments (17 segments/pa-
tient x 86 patients) the extent of LGE and SWMA were
significantly associated (p < 0.001). Of all segments, 403
(28%) had LGE and 472 (32%) SWMA. Abnormal motion
was found in 20% of segments without enhancement and
in 75% of segments enhancing more than 50%.Table 1 Final diagnoses of all cohort patients suspected
for nonischemic cardiomyopathy
All patients (n = 86)
Nonischemic cardiomyopathy* 65 (76)
Inflammatory cardiomyopathy 23 (27)
Dilated cardiomyopathy 22 (26)
Cardiomyopathy nonspecific 8 (9)
Infiltrative cardiomyopathy or storage disease 5 (6)
Noncompaction cardiomyopathy 3 (3)
Hypertrophic cardiomyopathy 2 (2)
Tako-Tsubo cardiomyopathy 1 (1)
Ion channelopathy (Long-QT syndrome) 1 (1)
Other diagnoses 21 (24)
Left ventricular hypertrophy** 15 (17)
Idiopathic arrhythmia 6 (7)
Values are n (%).
*Classification of (nonischemic) cardiomyopathies based on AHA 2006 guidelines
[1]. Cardiomyopathy nonspecific had characters of several cardiomyopathies.
**Hypertensive heart disease (n = 8) and left ventricular hypertrophy without
hypertension (n = 7).Baseline clinical characteristics and imaging parame-
ters of all study patients and patients discriminated with
the presence of LGE and SWMA are shown in Tables 2
and 3. At baseline, the presence of LGE (vs. absence of
LGE) and SWMA (vs. absence of SWMA) were signifi-
cantly associated with NYHA-class, CHF and LVEF.
Both LGE positive (vs. LGE negative) and SWMA positive
(vs. SWMA negative) patients had significantly higher
NYHA-class (II vs. I, p = 0.001 for both), more frequent
CHF (56% vs. 16%, p = 0.002; 64% vs. 7%, p < 0.001) and
decreased median LVEF on CMR (45% vs. 60%, p < 0.001;
42% vs. 65%, p < 0.001). At baseline, there were no signifi-
cant differences associated with the presence of LGE
(vs. absence of LGE), or SWMA (vs. absence of SWMA),
in myocardial injury biomarkers, arrhythmias or conduct-
ing abnormalities.
Follow-up
After CMR, patients were followed-up for MACE in me-
dian 835 (IQR: 780 – 998) days. Of 86 patients, altogether
15 (17%, annual event rate: 7.6%/year) reached an endpoint
during follow-up: 5 cardiovascular deaths, 2 cardiac trans-
plantations and 8 aborted sudden deaths.
Univariate Cox regression analysis was performed to
find significant unadjusted predictors of MACE during
follow-up, see Table 4. Significant predictors of adverse
outcome were NYHA-class III-IV (hazard ratio [HR] 2.8,
p = 0.049), sustained VT (HR 3.8, p = 0.023), atrioven-
tricular block of any degree (HR 3.8, p = 0.022), stroke
volume (HR 0.968, p = 0.032), LVEF on CMR (HR 0.959
per 1% increase in LVEF, p = 0.009), LGE volume (HR
1.028 per 1% increase in LGE, p < 0.001) and SWMA score
(HR 1.067 per 1 point increase in SWMA, p = 0.012).
Considering the presence of LGE, there was an event
rate of 26% (14 of 61) in LGE positive patients compared
with 4% (1 of 25) in LGE negative patients (p = 0.041,
Log rank), showing also a trend toward significance in
Cox regression (HR 6.3, p = 0.075). Correspondingly, the
presence of SWMA was a significant predictor of worse
outcome during follow-up (p = 0.002, Log rank), but the
hazard ratio was not calculated since there were no
events in the group of patients without SWMA.
Multivariate analysis was performed to find the ad-
justed predictors of MACE, see Table 5. The best overall
model to predict cardiac events included LGE volume
(HR 1.027, p = 0.003), sustained VT (HR 4.8, p = 0.011)
and LVEF (HR 0.962, p = 0.034).
ROC curves of LGE volume, SWMA score and LVEF
on CMR were analysed to find optimal cut-off values
for prediction of events during follow-up, with corre-
sponding area under curve (AUC) 0.832 (95% confi-
dence interval [CI]: 0.716 – 0.948), 0.769 (95% CI:
0.666 – 0.872) and 0.704 (95% CI: 0.565 – 0.844), see
Figure 1. The cut-off value with the best combination
Table 2 Baseline clinical characteristics of all patients, and patients discriminated with the presence of late gadolinium
enhancement (LGE) and segmental wall motion abnormality (SWMA)
All patients
(n = 86)
LGE negative
(n = 25)
LGE positive
(n = 61)
p-value SWMA negative
(n = 30)
SWMA positive
(n = 56)
p-value
Demographics
Age, year 53 (42–61) 49 (42–59) 53 (42–63) 0.278 51 (42–59) 53 (42–62) 0.336
Gender, female 39 (45) 15 (60) 24 (39) 0.131 20 (67) 19 (34) 0.007
Cardiovascular risk factors
Dyslipidemia 51 (59) 14 (56) 37 (61) 0.871 17 (57) 34 (61) 0.893
Hypertension 34 (40) 7 (28) 27 (44) 0.247 10 (33) 24 (43) 0.529
Diabetes 7 (8) 2 (8) 5 (8) 1.000 0 (0) 7 (13) 0.108
Smoking 19 (22) 6 (24) 13 (21) 1.000 6 (20) 13 (23) 0.944
Family risk for CAD 11 (13) 5 (20) 6 (10) 0.285 5 (17) 6 (11) 0.504
Sum of risk factors 1 (1–2) 1 (0–2) 1 (1–2) 0.513 1 (1–2) 1 (1–2) 0.406
Symptoms
Syncope or presyncope 21 (24) 9 (36) 12 (20) 0.185 9 (30) 12 (21) 0.536
Palpitation 34 (40) 13 (52) 21 (34) 0.204 14 (47) 20 (36) 0.448
Chest pain 31 (36) 9 (36) 22 (36) 1.000 12 (40) 19 (34) 0.746
NYHA-class 2 (1–3) 1 (1–2) 2 (1–4) 0.001 1 (1–2) 2 (1–4) 0.001
Congestive heart failure 38 (44) 4 (16) 34 (56) 0.002 2(7) 36 (64) < 0.001
Arrhythmias
Atrial fibrillation 25 (29) 6 (24) 19 (31) 0.688 5 (17) 20 (36) 0.109
Ventricular fibrillation 9 (10) 3 (12) 6 (10) 0.715 3 (10) 6 (11) 1.000
Sustained VT 9 (10) 1 (4) 8 (13) 0.274 1 (3) 8 (14) 0.152
Nonsustained VT 16 (19) 6 (24) 10 (16) 0.542 5 (17) 11 (20) 0.962
Conducting abnormalities
AVB of any grade 39 (45) 7 (28) 32 (53) 0.067 9 (30) 30 (54) 0.062
Distal AVB 7 (8) 3 (12) 4 (7) 0.409 3 (10) 4 (7) 0.691
Cardiac enzyme elevation* 32 (37) 8 (32) 24 (39) 0.693 9 (30) 23 (41) 0.436
Values are median (IQR) or n (%).
*Troponin T, Troponin I or CK-mb.
Abbreviations: AVB atrioventricular block, CAD coronary artery disease, IQR interquartile range, LGE late gadolinium enhancement, NYHA-class New York Heart
Association classification of functional capacity, SWMA segmental wall motion abnormality, VT ventricular tachycardia.
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(sensitivity: 80%; specificity: 78%), for SWMA extent
score of ≥ 5 (sensitivity: 80%; specificity: 68%) and for LVEF
the percentage of < 46% (sensitivity 73%; specificity: 65%).
Kaplan Meier curves of event-free survival of pa-
tients discriminated with the presence of LGE (Log
rank, p = 0.041) and with LGE volume ≥ 17% (Log rank,
p < 0.001) demonstrate that there was a high risk group
of 28 patients (LGE volume ≥ 17%) with 12 events and a
cumulative event ratio of 43% after three years (Figure 2A
and B). Patients with SWMA (p = 0.002, Log rank) and
patients with LVEF < 50% (p = 0.014, Log rank) were
also at increased risk (Figure 2C and D). Furthermore,
in the patient cohort with preserved LVEF (≥50%, 47
patients), the absence of SWMA (30 patients) resulted in
no events during follow-up, but 17 patients with SWMAwere still at risk with 4 events (Log Rank, p = 0.005)
(Figure 2E).
Discussion
This study shows that in patients with suspected NICM,
mainly presenting with ventricular arrhythmias or CHF,
the extent of LGE on CMR independently predicts
MACE compared to traditional risk factors. Even though
the final diagnosis is uncertain, extensive amount of LGE
should be considered as a sign of poor prognosis and ac-
tivate more intensive diagnostics and surveillance. Fur-
thermore, the absence of SWMA on CMR was a strong
predictor of good prognosis with no cardiac events dur-
ing follow-up, giving additional prognostic information
also in the subgroup of patients with preserved LVEF
(≥50%).
Table 3 Baseline imaging parameters of all patients, and patients discriminated with the presence of late gadolinium
enhancement (LGE) and segmental wall motion abnormality (SWMA)
All patients
(n = 86)
LGE negative
(n = 25)
LGE positive
(n = 61)
p-value SWMA negative
(n = 30)
SWMA positive
(n = 56)
p-value
Echocardiography
LVEDD, mm 55 (48–61) 48 (44–54) 56 (50–63) < 0.001 48 (44–54) 59 (53–67) < 0.001
LVEF, % 50 (33–62) 62 (57–71) 42 (25–56) < 0.001 63 (60–70) 38 (23–52) < 0.001
CMR
LVEDV, ml/m2 78 (64–110) 71 (60–82) 87 (66–111) 0.050 68 (60–76) 97 (69–120) < 0.001
LVESV, ml/m2 36 (25–69) 26 (21–32) 46 (30–73) 0.001 25 (20–31) 55 (35–85) < 0.001
SV, ml 73 (58–85) 75 (65–89) 72 (55–84) 0.227 76 (65–82) 70 (52–88) 0.291
LVEF, % 52 (35–61) 60 (56–69) 45 (32–58) < 0.001 65 (59–69) 42 (30–53) < 0.001
LGE presence 61 (71) - - - 9 (30) 52 (93) < 0.001
LGE extent, score 5 (0–17) - 9 (4–22) - 0 (0–2) 11 (4–23) < 0.001
LGE extent, % LV volume 7 (0–25) - 13 (6–32) - 0 (0–3) 16 (6–34) < 0.001
SWMA, presence 56 (65) 4 (16) 52 (85) < 0.001 - - -
SWMA extent, score 4 (0–12) 0 (0–0) 5 (3–17) < 0.001 - 7 (4–19) -
Values are median (IQR) or n (%).
Abbreviations: CMR cardiovascular magnetic resonance, IQR interquartile range, LV left ventricular, LVEF left ventricular ejection fraction, LGE late gadolinium
enhancement, LVEDD left ventricle end-diastolic diameter, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end-systolic volume, SV stroke volume,
SWMA segmental wall motion abnormality.
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In our study, for every 1% increase in LGE volume, the
risk of reaching MACE during follow-up increased 2.7%,
independently of sustained VT and LVEF. The highest
event rate was observed in the patients with LGE vol-
ume of ≥ 17%, with a cumulative event ratio of up to
43%.
In earlier studies, the prognostic value of LGE has
been documented in several disease entities of NICM. In
DCM, the presence and extent of LGE, typically mid-
wall replacement fibrosis, has been shown to provide
independent and incremental prognostic information
[12,13,17]. In hypertrophic cardiomyopathy (HCM), the
presence and extent of LGE predict adverse outcome
[10,11] and lately in a systematic meta-analysis of 1,063
patients with HCM, during 3.1-year follow-up, the pres-
ence of LGE was associated with cardiac death and all-
cause mortality [26]. In suspected cardiac amyloidosis a
characteristic circumferential endomyocardial LGE is a
stronger predictor of mortality compared to other non-
invasive parameters [15], and in suspected cardiac sarcoid-
osis the presence of LGE was the best adjusted predictor
of adverse cardiac events [27]. Also, the presence of LGE
has been shown to be the best independent predictor of
mortality in biopsy-proven viral myocarditis compared to
traditional cardiac signs and symptoms [28].
However, there is limited information on the prognos-
tic value of LGE in nonselected consecutive patients
with suspected or newly diagnosed NICM, reflecting the
common clinical setting, and whether the quantificationof LGE provides additional prognostic information in
these patients. In a recent study of patients with newly
diagnosed NICM, the presence of LGE was associated
with worse prognosis, although only traditional risk
markers, such as LV performance and cardiac bio-
markers, were independent prognostic factors [8]. Our
study adds to previous studies, that in clearly symptomatic
patients with suspected NICM, the extent of LGE, along
with its presence, carries prognostic value.
Of our study cohort, 76% of patients were eventually
diagnosed with NICM, including 27% of patients with
inflammatory cardiomyopathy. The histological basis for
LGE in this sample was probably heterogenic, including
replacement fibrosis, necrosis, oedema or amyloid infil-
tration. Patients with inflammatory cardiomyopathy may
have wide-spread amounts of less intense LGE compared
to myocardial infarction [29]. In this study, the optimal
cut-off value for LGE extent for event prediction during
follow-up was a volume of ≥ 17%. This is higher com-
pared to a recent cohort study of patients with nonis-
chemic DCM with an indication for ICD, where the
optimal cut-off value of LGE extent was 6.1% for event
prediction [16]. This difference in cut-off values is prob-
ably explained by different patient cohorts; our study did
not include just patients with DCM but patients with
suspected NICM, of which 27% had finally inflammatory
cardiomyopathy having higher LGE volume in LGE posi-
tive patients (mean 22% [median 13%]) compared to DCM
patients (mean 9%) in the other study. This demonstrates
the importance of taking into account the reference patient
Table 4 Univariate Cox regression analysis of event-free
survival
HR 95% CI p-value
Demographics
Age, year 1.020 0.980 - 1.060 0.333
Gender, female 1.094 0.397 - 3.016 0.863
Symptoms
Syncope or presyncope 1.093 0.348 - 3.434 0.879
Palpitation 1.369 0.497 - 3.777 0.544
Chest pain 0.837 0.286 - 2.449 0.745
NYHA-class (III - IV) 2.820 1.003 - 7.928 0.049
Congestive heart failure 2.704 0.924 - 7.913 0.069
Arrhythmias
Atrial fibrillation 2.256 0.818 - 6.223 0.116
Ventricular fibrillation 0.559 0.073 - 4.250 0.574
Sustained VT 3.807 1.207 - 12.013 0.023
Nonsustained VT 1.122 0.317 - 3.975 0.859
Conducting abnormalities
AVB of any grade 3.801 1.210 - 11.945 0.022
Distal AVB 0.758 0.100 - 5.764 0.789
Cardiac enzyme elevation* 1.540 0.558 - 4.247 0.404
CMR
LVEDV, ml/m2 1.004 0.991 - 1.016 0.556
LVESV, ml/m2 1.008 0.996 - 1.020 0.213
SV, ml 0.968 0.940 - 0.997 0.032
LVEF, % 0.959 0.930 - 0.990 0.009
LVEF < 50% 3.813 1.213 -11.981 0.022
LGE, presence 6.329 0.832 - 48.143 0.075
LGE, extent, score 1.042 1.019 - 1.065 < 0.001
LGE, extent, % LV volume 1.028 1.013 - 1.044 < 0.001
SWMA, presence** 0.002
SWMA, extent, score 1.067 1.014 - 1.122 0.012
*Troponin T, Troponin I or CK-mb.
**HR was not calculated for the presence of SWMA, since there were no events in
the group of patients without SWMA; Univariate p-value was walculated with Log
rank test.
Abbreviations: AVB atrioventricular block, CAD coronary artery disease,
CI confidence interval, CMR cardiovascular magnetic resonance, HR hazard ratio,
LV left ventricular, LVEF left ventricular ejection fraction, LGE late gadolinium
enhancement, LVEDD left ventricle end-diastolic diameter, LVEDV left ventricle
end-diastolic volume, LVESV left ventricle end-systolic volume, NYHA-class New
York Heart Association classification of functional capacity, SV stroke volume,
SWMA segmental wall motion abnormality, VT ventricular tachycardia.
Table 5 Multivariate Cox regression analysis of event-free
survival
HR 95% CI p-value
Model (forward stepwise)
LGE extent, % LV volume 1.027 1.009 - 1.044 0.003
Sustained VT 4.793 1.428 - 16.087 0.011
LVEF (CMR), % 0.962 0.929 - 0.997 0.034
Abbreviations: CI confidence interval, HR hazard ratio, LGE late gadolinium
enhancement, LV left ventricular, LVEF left ventricular ejection fraction,
VT ventricular tachycardia.
Figure 1 Receiver operating characteristic curves of late
gadolinium enhancement (LGE) volume, segmental wall
motion abnormality (SWMA) score and left ventricular
ejection fraction (LVEF) for prediction of events during
follow-up, with corresponding area under curve 0.832
(95% confidence interval [CI]: 0.716 – 0.948), 0.769 (95% CI:
0.666 – 0.872) and 0.704 (95% CI: 0.565 – 0.844). In the patient
cohort of suspected nonischemic cardiomyopathy with relatively
high prevalence of LGE and SWMA (71% and 65% of patients) at
baseline, the optimal cut-off values with the best combination of
sensitivity and specificity were LGE volume of ≥ 17%, SWMA score
of ≥ 5 and LVEF < 46%.
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LGE in risk prediction. Also, importantly, after the etiology
of NICM is diagnosed, LGE volume should be interpreted
in the context of that disease.
The HR of 1.027 associated with LGE extent in pre-
dicting MACE was smaller compared to recent studies
of DCM (HR = 1.11 or HR = 1.16) [16,17], but similar toa recent study of 217 consecutive HCM patients, in which
LGE extent was associated with HR 1.15 for each 5% in-
crease in LGE volume [10]. The mean LGE extent (in LGE
positive patients) was similar between our study patients
and HCM study patients (22% vs. 15.5%), but higher com-
pared to DCM study patients (median 2.5% in the other,
mean 9% in the other). Hence, in the sample of patients
with relatively large amounts of LGE, a very small increase
in LGE extent does not necessarily cause clinically mean-
ingful increase in risk, although statistically significant.
Prognostic value of segmental wall motion abnormality
In this study SWMA on CMR was present in 65% of pa-
tients. The unadjusted SWMA score predicted MACE
Figure 2 Kaplan Meier analysis of event-free survival during follow-up in patients discriminated with the presence of late gadolinium
enhancement (LGE) on cardiovascular magnetic resonance (CMR) (A), with LGE volume of ≥ 17% (B), with the presence of segmental
wall motion abnormality (SWMA) (C), and with left ventricular ejection fraction (LVEF) of < 50% (D). In the patient cohort with preserved
LVEF (≥50%), the absence of SWMA (30 patients) resulted in no events during follow-up, while 17 patients with SWMA were still at risk with 4
events (E).
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associated with 6.7% increase in risk), but not independ-
ently of traditional prognostic factors such as LVEF. It is
natural that SWMA score and LVEF have strong inter-
relation, since they both are measures of global LV func-
tion [24]. However, the absence of SWMA was a strong
predictor of good prognosis in our patients. Further-
more, SWMA may also give prognostic information be-
yond preserved LVEF (≥50%), since in this subgroup
patients with SWMA were still at risk for further events,
although data was small.
Study limitations
This study employs an observational follow-up study de-
sign. The number of patients enrolled to the study and
who eventually reached MACE during follow-up was
limited. However, all endpoints were life-threatening
events. The patient cohort with suspected NICM at
presentation was heterogenic in final diagnoses. Thus,
the results of this study should not be interpreted in spe-
cific cardiac disease entities. However, patients with sus-
pected NICM reflect the real-life setting in which the
need of CMR is considered. In this study we did not
evaluate the additional prognostic value of LGE or
SWMA in relation to final diagnoses, although it is
known that the etiology of NICM has influence in out-
come [3]. Also, it must be reminded that LGE visualizes
only myocardial enhancement in relation to “normal”
myocardium and has limited ability to detect diffuse
myocardial changes. Recently introduced extracellular
volume quantification method based on gadolinium-
enhanced CMR and myocardial T1-mapping seems to
be useful in detecting diffuse myocardial fibrosis or
homogeneously distributed infiltration, seen in many
forms of NICM, thus potentially providing further prog-
nostic information [30]. Finally, the presented cut-off
values for LGE extent in this study represent only our
patient sample, demonstrating the effect of increasing
LGE on patient outcomes, and should be tested in inde-
pendent study population.
Conclusions
In suspected NICM, presenting with ventricular arrhyth-
mias or heart failure, LGE extent gives additional prog-
nostic information compared to traditional risk factors,
while the absence of segmental wall motion abnormality
may give prognostic information beyond normal LVEF.
Even though the final diagnosis is uncertain in NICM,
extensive amount of LGE should be considered as a sign
of poor prognosis and activate more intensive diagnos-
tics and surveillance.
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